Missed acute pulmonary embolism and sudden death: A case report

Yasser Mohammed Hassanain Elsayed

Critical Care Unit, Fraskour Central Hospital, Egypt

ARTICLE INFO

Article history:
Received 17 March 2019
Revision 7 April 2019
Accepted 20 May 2019
Available online 27 May 2019

Keywords:
Missed acute pulmonary embolism
Sudden death
Ignorance
Diagnosis
Pulmonary embolism

1. Introduction

Pulmonary embolism (PE) is an important manifestation of venous thromboembolism (VTE), which is the third most frequent fatal cardiovascular disease [1,2]. Indeed, the annual incidence of PE is 100-200 per 100,000 inhabitants [2]. Nearly, 33.4% of patients with VTE presented with PE, and 66.6% manifested with deep vein thrombosis (DVT) [1]. Approximately, 500,000-600,000 cases of acute PE (APE) were reported yearly in the US [3]. Nearly, 150,000-200,000 of APE patients represented either primary or secondary cause of death [3]. The mortality rate of treated APE ranged from 3% to 8%, but the rate elevated to around 30% in untreated cases [3]. The lower limb DVT was reported in nearly 70% of sustained APE, with the remaining 30%, has already become detached embolism. On contrariwise, APE occurred in approximately 50% of proximal lower limb DVT [4]. APE is a prevalent and potentially-lethal disease with high morbidity and mortality [5]. APE may be classified into three categories: massive, sub-massive, and non-massive [6]. Massive APE is defined as hemodynamic instability or systolic hypotension, lower than 90 mmHg. The cases of massive APE are the most serious class that indicates prompt thrombolitics. Sub-massive APE refers to the presence of right ventricular dysfunction (RVD) without hemodynamic instability [5]. Though RVD can be firstly diagnosed with echocardiography, the sub-massive APE carries higher morbidity and mortality than those without RVD [5]. Otherwise, the APE not under the definitions of massive or sub-massive embolism is usually named as non-massive type [5]. Confirmed APE is defined as a probability of PE high enough to indicate the need for PE-specific treatment [2]. Excluded APE is a low likelihood of APE enough to withholding the specific treatment [2]. The risk factors of APE are as followings: postoperative...
hypertension with shock (20%), hypoxaemia on arterial blood gases (26%), tachypnea with respiratory rate more than 20/min (75%), death (25%), sinus tachycardia with heart rate more than 100/min (49%), signs of unilateral DVT (33%), totally asymptomatic (16%), sudden fever with temperature higher than 38.5 °C (28%), cough (17%), signs of unilateral DVT (33%), totally asymptomatic (16%), sudden death (25%), sinus tachycardia with heart rate more than 100/min (26%), tachypnea with respiratory rate more than 20/min (75%), hypotension with shock (20%), hypoxaemia on arterial blood gases (75%), electrocardiographic right ventricular hypertrophy (50%) and radiological; atelectasis (49%), pleural effusion (51%), raised hemidiaphragm (36%), peripheral opacification with infarct (33%), and lung oligemia (36%) [2,5,7,9,10].

During diagnosis, clinical stability, and the pre-test probability will determine the diagnostic approach [2,8]. APE is suspected by the signs of dyspnea, chest pain, pre-syncope or syncope, and hemoptysis [2]. Hypotension and cardiogenic shock are rare symptoms that can indicate PE [2,7]. Chest pain is a frequent symptom of APE and is usually caused by pleural irritation due to distal emboli resulting in pulmonary infarction. For patients with central PE, chest pain may have typical anginal [2] or have acute and severe dyspnea; while for patients with small peripheral PE, these symptoms are often mild and transient. However, deterioration of dyspnea may be the only sign indicative of APE especially in patients with preexistent HF or respiratory disease [2]. Clinical probability should be assessed in all suspected cases of APE [2]. Different diagnoses should always be considered until APE exclusion [11]. Testing of d-dimer should be used after the evaluation of clinical probability [11], but the testing should not be done in the patients with a higher clinical probability of APE. A negative d-dimer test strongly excludes APE in the cases of low or intermediate clinical probability [11]. Computed tomography pulmonary angiogram (CTPA) is a choice of radiological lung modality for non-massive APE, and negative CTPA indicates no further investigation or treatment for APE [11]. CTPA or echocardiography (ECHO) will strongly confirm the massive APE [11]. The electrocardiography (ECG) is often abnormal in APE, and only 33% of patients have normal ECG [12]. Lack of specificity and sensitivity of ECG signs pose a challenge to the diagnosis of APE [12]. The most common ECG findings in APE patients are sinus tachycardia, right bundle branch block, T-wave inversion/ST-segment deviations (V1-3), low QRS voltage, McGinn-White sign, and right axis deviation [12]. Anticoagulation is the mainstay of VTE treatment [2]. Surprisingly, the low-molecular-weigh heparin is a choice of therapy for inpatient cases [11]. However, transient risk factors may affect the final decision on the duration of anticoagulants after the first attack of APE [2]. The current guidelines encourage thrombolytic drugs in the cases with hypotension or shock secondary to APE [9]. Unstable APE with minimal bleeding will be alleviated by thrombolytics [1] that is the therapeutic choice for massive APE [11].

2. Case report

A 42-year-old married, Egyptian male accountant presented with severe acute chest pain. Profuse sweating, dizziness on sitting, and increased breathing were the associated symptoms. An informed consent has been signed by the patient’s family. The patient gave a recent history of burning sensation in his chest one week ago, and he denied the history of cardiovascular diseases, smoking, drugs or any special habits. He was managed by internist physician as gastroesophageal reflux disease. Omeprazole capsule (20 mg, twice daily), ranitidine tablet (150 mg, twice daily) were prescribed for one week. The general condition became more deteriorated and the chest pain gradually worse. There was no any signs of improvement rather than deterioration. Chest pain had become compressible. The patient was brought by his family for consultation from the cardiologist (author) at 2 o’clock after midnight at the clinic outpatient. The cardiologist urgently called the ambulance for hospital referral. O₂ inhalation was given with generator (100%, by nasal cannula, 5 L/min) before the ambulance arrived. Urgent ECG was done. Unfortunately, the cardiac arrest had happened. Cardiopulmonary resuscitation according to the current guidelines was proceeded by the cardiologist at his clinic outpatient but regrettably with no response. Upon general physical examination, the patient undergone tachypnea, central cyanosis, dyspnea, severe sweaty, and had cold extremities, with a regular heart rate of 135 bpm, blood pressure of 70/40 mmHg, respiratory rate of 60 bpm, the temperature of 36.1 °C, pulse oximeter of O₂ saturation of 63% (normally; 95%-100%) and tachycardia on heart auscultation. No more relevant clinical data were noted during the clinical examination. The case was initially managed as a suspected APE with shock. Massive APE was the most probable diagnosis. Several ECG tracings were taken that showed sinus tachycardia, SIQ3T3 pattern, incomplete right bundle branch block, P-pulmonal, and ST-segment depressions in V1-3 leads (Figure 1). The only measured random blood sugar was 213 mg/dL (normally ≤200 mg/dL). No more workup was done.
This APE case started with mild phase and progressed to massive embolism. Pleuritic chest pain was indicating mild APE or pulmonary infarction. But compressive anginal chest pain, hypotension, and central cyanosis were serious signals for massive APE. Sinus tachycardia may be presented with both fatal and non-fatal embolisms. McGinn-White sign or S1Q3T3 pattern is presented in about 8% of massive APE but with may normal variant. An incomplete right bundle branch block with anterior ST-segment depressions in V1, V3 leads, P-pulmonal are mostly signs of acute severe RVD.

The death in this case is due to ignorance in clinical diagnosis. The patient was not advised for urgent d-dimer assay or computed tomography pulmonary angiogram per se, and was not considered as APE at the beginning. Accurate diagnosis of APE would help save the life. Physicians should pay more attention on related symptoms and signs of APE.

It is important to make differential diagnosis among several diseases, such as acute coronary syndrome, aortic dissection, acute pericarditis, asthma, pneumonia, chronic obstructive pulmonary disease exacerbation, acute pulmonary edema, aortic dissection, pneumothorax, bronchogenic carcinoma, primary pulmonary hypertension, chest trauma with rib fracture, musculoskeletal chest pain, anxiety disorders, and hysteria. We can’t compare the current case to other studies due to absent of similar condition. It is recommended to pay more attention to the identification of APE.

**Conflict of interest statement**

The author reports no conflict of interest.

**References**

[1] Wilbur J, Shian B. Deep venous thrombosis and pulmonary embolism: Current therapy. *Am Fam Physician* 2017; 95(5): 295-302.

[2] Stavros V, Adam T, Giancarlo A, Nicolas D, David F. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *EHJ* 2014; 35: 3033-3080. DOI:10.1093/eurheartj/het283

[3] Nagamalesh UM, Prakash VS, Naidu KCK, Sarthak S, Hegde AV, Abhinay T. Acute pulmonary thromboembolism: Epidemiology, predictors, and long-term outcome-A single center experience. *Indian Heart J* 2017; 69(2): 160-164.

[4] Riedel M. Venous thromboembolic disease: Acute pulmonary embolism I: pathophysiology, clinical presentation, and diagnosis. *Heart* 2001;
85(2): 229-240.
[5] Ritesh A, Subhash V. Acute pulmonary embolism. *Eastern J Med* 2009; 14(2): 57-68.

[6] Torbicki A, Perrrier A, Konstantinides S, Agnelli G, Galliè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Heart J* 2008; 29(18): 2276-2315.

[7] Kostadima E, Zakynthinos E. Pulmonary embolism: Pathophysiology, diagnosis, treatment. *Hellenic J Cardiol* 2007; 48(2): 94-107.

[8] 2013 Thrombosis Canada. Pulmonary embolism: Diagnosis and management. *Thrombosis Canada* 2013; 1-9. [Online] Available from: http://thrombosiscanada.ca/guides/pdfs/PE.pdf.

[9] Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounaumes H, Goldhaber S, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012; 141(Suppl 2): e419S-e496S.

[10] Bálohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. *Exp Clin Cardiol* 2013; 18(2): 129-138.

[11] British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. BTS guidelines for the management of suspected acute pulmonary embolism. *Thorax* 2003; 58(6): 470-484.

[12] Mehmet M, Cana, E C, Burak T, Cihangir K. Atipic electrocardiographic manifestation of pulmonary embolism. *Resuscitation* 2010; 81: 1738-1739.